Hair, Skin & Tanning Peptides: A Research-First Guide to MT2 and GHK-Cu (Plus Our Glow Line)

For research and educational purposes only. Peptide Supply products are not intended to diagnose, treat, cure, or prevent any disease. Many peptides discussed below are not approved as drugs for cosmetic tanning or anti-aging use. Always follow applicable laws, lab safety standards, and consult qualified professionals for clinical questions.

Hair, skin, and pigmentation biology is controlled by a surprisingly small set of signaling “switches.” In the research world, two of the most-discussed categories are:

  • Melanocortin receptor agonists (e.g., MT2 / Melanotan II) that influence melanin production and pigmentation pathways.
  • Carrier peptides (e.g., GHK-Cu) that bind copper and are studied for extracellular matrix remodeling, skin quality markers, and follicle-support signaling.

This guide goes deep on every product in our Hair, Skin & Tanning lineup and explains what the literature actually supports—plus what it doesn’t.

Shop the Category & Products Mentioned

1) MT2 (Melanotan II): Pigmentation Signaling via the Melanocortin System

What MT2 is (in plain English)

MT2 is a synthetic analog of α-MSH (alpha-melanocyte stimulating hormone). It’s studied because it can activate melanocortin receptors, especially MC1R on melanocytes—cells that produce melanin. More melanin (particularly eumelanin) generally corresponds to darker pigmentation.

Core mechanism: MC1R activation → eumelanin signaling

When melanocortin signaling increases at MC1R, melanocytes upregulate pathways involved in melanin synthesis. This is the central biological rationale behind studying MT2 for pigmentation outcomes. DermNet’s clinical overview summarizes MT2 as an unlicensed melanocortin agonist associated with pigmentation changes and adverse effects in reported use.

What human evidence exists?

Controlled human data for MT2 is limited relative to approved melanocortin therapies. However, early phase work exists. In a pilot phase I human study, Dorr et al. evaluated MT2 and reported dose-related pigmentation effects (alongside side effects like nausea/somnolence in some participants). This is one of the most-cited early clinical investigations into MT2’s melanotropic activity.

Important distinction: MT2 vs. approved melanocortin therapy

It’s common to see MT2 discussed next to afamelanotide (Melanotan I), which is a different compound and has undergone much more rigorous clinical testing for specific medical indications. For example, in the New England Journal of Medicine, Langendonk et al. reported phase 3 trial outcomes for afamelanotide in erythropoietic protoporphyria (EPP), demonstrating increased pain-free light exposure with an acceptable adverse-event profile in that population. This does not validate MT2 for cosmetic tanning; it simply shows that melanocortin biology can be clinically meaningful under controlled conditions.

Safety & risk signals researchers should take seriously

MT2 is widely described as unregulated/unlicensed for tanning and has a track record of adverse-event reports (e.g., nausea, flushing, changes in moles/pigmentation patterns). A dedicated literature review titled “An unhealthy glow? A review of melanotan use and associated clinical outcomes” summarizes reported clinical outcomes and concerns from the published record. There are also more recent medical discussions of mucosal/oral changes associated with MT2 injections in the literature.

Research takeaway: MT2’s tanning mechanism is biologically plausible and supported by early-phase data showing pigmentation changes, but the safety profile is not established for consumer cosmetic tanning, and adverse outcomes have been reported. Any legitimate discussion must include these constraints.

2) GHK-Cu (Copper Tripeptide-1): Skin Quality, ECM Remodeling & Follicle Signaling

GHK is a naturally occurring human tripeptide (Gly-His-Lys) that binds copper to form GHK-Cu. In the literature, it’s often framed as a carrier peptide with downstream effects on extracellular matrix (ECM) biology, inflammation signaling, and tissue remodeling markers.

Why copper binding matters

Copper is a catalytic cofactor in multiple biological processes relevant to skin structure (including enzymes involved in connective tissue and redox balance). GHK’s affinity for copper is part of why GHK-Cu is studied as a signaling and remodeling modulator rather than a simple “moisturizing” ingredient.

Key skin mechanism themes in the literature

  • Collagen/ECM signaling: In vitro work by Maquart et al. reported stimulation of collagen synthesis in fibroblast cultures with GHK-Cu, supporting the “matrix remodeling” hypothesis.
  • Regeneration/repair framing: MDPI reviews on copper peptides (including “Skin Regenerative and Anti-Cancer Actions of Copper Peptides” and “Regenerative and Protective Actions of the GHK-Cu Peptide…”) summarize broad preclinical and translational findings: wound-healing models, antioxidant enzyme activity, and tissue quality markers.
  • Cosmetic outcomes (limited but notable clinical signals): A randomized, double-blind topical study design using a GHK-Cu nano-carrier has been described in the literature and secondary summaries; it is frequently cited as showing improvements in wrinkle parameters over weeks of use (interpretation depends on formulation, endpoints, and study quality).

Hair & scalp research: what’s actually supported?

GHK-Cu appears in hair/scalp discussions because dermal papilla cells and follicle microenvironments respond strongly to growth factors, inflammatory signals, vascular support, and ECM integrity. A classic in vitro publication, “The effect of tripeptide-copper complex on human hair growth in vitro” (available via Springer) describes hair-related cellular and growth-factor changes in controlled settings. More recent reviews also discuss how copper peptides may relate to follicle signaling (e.g., VEGF-related pathways), but researchers should distinguish mechanistic plausibility from proven clinical hair regrowth efficacy.

What to expect (realistically) from the evidence

Research takeaway: Compared with tanning peptides, GHK-Cu has a broader “skin quality” and “tissue remodeling” evidence base (especially preclinical and mechanistic). Human cosmetic outcomes exist but vary by formulation and study design. It’s best described as a multi-pathway skin and scalp support peptide with strong mechanistic rationale and mixed levels of clinical proof depending on endpoint.

3) GHK-Cu 100mg vs GHK-Cu 50mg: Same Peptide, Different Format

These are the same active compound—GHK-Cu—offered in different quantities for different research throughput:

  • GHK-Cu 50mg: ideal for smaller pilot experiments, protocol optimization, or labs running multiple conditions.
  • GHK-Cu 100mg: better for extended studies, repeat assays, or higher sample counts.

Selection tip: choose based on experimental volume, number of conditions, and your planned repeats—not because the biology differs.

4) KLOW, GLOW 70, and GLOW 50: Research Stacks for Skin-Forward Study Designs

In peptide research, “stack” products are typically designed to simplify study workflows by grouping complementary signaling goals (e.g., pigment pathway support + skin quality support + recovery-support concepts). Your products:

Important: Because formulas can change and because I’m not pulling your internal composition sheet here, I’m not going to guess ingredients or make claims about what’s inside. Instead, here’s how to describe them accurately and compliantly—based on the science themes customers usually want:

KLOW: “Complexion-first” positioning (without medical claims)

KLOW can be framed as a skin appearance research stack—focused on the research themes people care about most:

  • Visible radiance and “skin quality” markers
  • Barrier-support and recovery signaling concepts
  • Complementary pairing with GHK-Cu-type remodeling concepts (where relevant)

GLOW 70 vs GLOW 50: two tiers for different research goals

Use “tiering” language to keep it simple for customers:

  • GLOW 50 can be described as the entry tier for glow/skin-quality experimentation—useful for pilots and conservative designs.
  • GLOW 70 can be described as the higher-intensity tier for labs that want broader or more concentrated “skin quality” exploration—useful for extended protocols or higher-throughput work.

How to keep this credible: On each product page, list the exact actives and link back to this article. In this article, avoid implying a specific ingredient list unless you publish it.

Bottom Line

  • MT2 is best understood as a melanocortin agonist studied for pigmentation effects, with early human evidence for tanning signals but significant safety and regulatory concerns.
  • GHK-Cu is a copper-binding carrier peptide with extensive mechanistic research related to tissue remodeling and skin quality markers, and some human cosmetic studies depending on formulation.
  • GHK-Cu 50mg vs 100mg is a scale choice, not a biology choice.
  • KLOW / GLOW 50 / GLOW 70 should be positioned as skin-forward research stacks, with claims tied to published mechanisms and transparent ingredient listings on the product pages.

Studies & References (Links)

  1. Dorr RT et al. “Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.” Life Sciences (1996). https://www.sciencedirect.com/science/article/abs/pii/0024320596001609
  2. Langendonk JG et al. “Afamelanotide for Erythropoietic Protoporphyria.” New England Journal of Medicine (2015). https://www.nejm.org/doi/pdf/10.1056/NEJMoa1411481
  3. Brennan R et al. “An unhealthy glow? A review of melanotan use and associated clinical outcomes.” (ScienceDirect). https://www.sciencedirect.com/science/article/pii/S2211266915000055
  4. Maquart FX et al. “Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex (GHK-Cu).” FEBS Letters (1988). https://www.sciencedirect.com/science/article/pii/001457938880509X
  5. Springer PDF. “The effect of tripeptide-copper complex on human hair growth in vitro …” https://link.springer.com/content/pdf/10.1007/BF02978833.pdf?pdf=button
  6. MDPI. “Skin Regenerative and Anti-Cancer Actions of Copper Peptides.” https://www.mdpi.com/2079-9284/5/2/29
  7. MDPI. “Regenerative and Protective Actions of the GHK-Cu Peptide in the Skin.” https://www.mdpi.com/1422-0067/19/7/1987
  8. MDPI (2026). “Changes in Oral Mucosa Associated with Melanotan II Injections …” https://www.mdpi.com/2075-1729/16/2/265